Antibodies
18 November 2013
Actinium Pharmaceuticals Announces Plans For Iomab™-B Phase 3 Pivotal Trial Following Meeting With FDA16 November 2013
Roche presents lampalizumab biomarker data from phase II study in advanced form of dry macular degeneration14 November 2013
Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology11 November 2013
ImmunoGen, Inc. Announces Fifth New License Agreement in 201311 November 2013
MacroGenics DART Therapeutic Selected by Boehringer Ingelheim as a Bi-Specific Pre-Clinical Development Candidate11 November 2013
Soliris® (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (aHUS)8 November 2013
INNATE PHARMA: Launch of IND-Enabling studies for IPH41027 November 2013
Bayer Submits VEGF Trap-Eye (aflibercept solution for injection) for Treatment of Diabetic Macular Edema in the EU6 November 2013
Emergent BioSolutions Presents Preclinical Data on ES414, Its Lead Bispecific ADAPTIR Therapeutic for Prostate Cancer5 November 2013
ImmunoGen, Inc. Announces Discontinuation of IMGN901 Study in Small-Cell Lung Cancer (SCLC)5 November 2013
Theraclone Sciences’ Monoclonal Antibody Candidate PGT121 Suppresses HIV in Simian Models of Disease4 November 2013
GeNeuro Successfully Completes Phase 2a Clinical Study with Novel Approach to Treat Multiple SclerosisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports